

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

		CASE		CONTROL	
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TRIO	SINGLETON
N=:		91	346	169	277
RASS Patient N=:		0	0	15	30
SEX (%):	male	38 (41.8 %)	172 (49.7 %)	56 (33.1 %)	96 (34.7 %)
AGE AT ENTRY:	n	91	346	169	277
	mean (std)	41.2 (6.8)	44.3 (6.8)	34.2 (8.4)	38.7 (8.6)
	minimum	28.0	23.0	18.0	19.0
	25th-percentile	36.0	40.0	27.0	32.0
	median	40.0	45.0	33.0	39.0
	75th-percentile	47.0	49.0	41.0	46.0
	maximum	54.0	59.0	53.0	55.0
RACE:	white	82 (90.1 %)	297 (85.8 %)	162 (95.9 %)	264 (95.3 %)
	black	0 (0.0 %)	13 (3.8 %)	1 (0.6 %)	3 (1.1 %)
	hispanic	9 (9.9 %)	27 (7.8 %)	1 (0.6 %)	0 (0.0 %)
	american indian/alas	0 (0.0 %)	4 (1.2 %)	1 (0.6 %)	1 (0.4 %)
	other	0 (0.0 %)	3 (0.9 %)	2 (1.2 %)	6 (2.2 %)
	missing	0 (0.0 %)	2 (0.6 %)	2 (1.2 %)	3 (1.1 %)
DURATION of DIABETES (yrs):	n	91	346	169	277
	mean (std)	30.4 (7.5)	31.9 (7.8)	22.9 (7.1)	24.9 (7.2)
	minimum	15.0	11.0	15.0	15.0
	25th-percentile	25.0	27.0	17.0	19.0
	median	29.0	32.0	21.0	24.0
	75th-percentile	36.0	37.0	26.0	29.0
	maximum	50.0	52.0	45.0	52.0

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		TRIO	SINGLETON	TRIO	SINGLETON
NOW ON INSULIN(NON-PANCR. TRANS.)	no	0 (0.0 %)	1 (0.8 %)	0 (0.0 %)	0 (0.0 %)
	yes	44 (100.0 %)	131 (99.2 %)	169 (100.0 %)	277 (100.0 %)
INSUL. REGIMEN(NON-PANCR. TRANS.)	<2 Shots	3 (6.8 %)	12 (9.1 %)	9 (5.3 %)	14 (5.1 %)
	MDI	18 (40.9 %)	64 (48.5 %)	66 (39.1 %)	130 (46.9 %)
	pump	21 (47.7 %)	50 (37.9 %)	90 (53.3 %)	120 (43.3 %)
	missing	2 (4.5 %)	6 (4.5 %)	4 (2.4 %)	13 (4.7 %)
INSULIN DOSAGE(units/kg/day):	n	40	121	155	261
	mean (std)	0.6 (0.2)	0.6 (0.2)	0.6 (0.2)	0.6 (0.2)
	minimum	0.3	0.1	0.2	0.0
	25th-percentile	0.5	0.4	0.5	0.5
	median	0.6	0.5	0.6	0.6
	75th-percentile	0.7	0.7	0.7	0.7
FOCAL LASER TREATMENT:	no	51 (56.0 %)	229 (66.2 %)	166 (98.2 %)	267 (96.4 %)
	yes	20 (22.0 %)	67 (19.4 %)	2 (1.2 %)	10 (3.6 %)
	unknown	18 (19.8 %)	48 (13.9 %)	1 (0.6 %)	0 (0.0 %)
	missing	2 (2.2 %)	2 (0.6 %)	0 (0.0 %)	0 (0.0 %)
PAN-RETINAL LASER TREATMENT:	no	13 (14.3 %)	48 (13.9 %)	153 (90.5 %)	246 (88.8 %)
	yes	71 (78.0 %)	281 (81.2 %)	13 (7.7 %)	27 (9.7 %)
	unknown	6 (6.6 %)	14 (4.0 %)	2 (1.2 %)	2 (0.7 %)
	missing	1 (1.1 %)	3 (0.9 %)	1 (0.6 %)	2 (0.7 %)
ESRD:	no	15 (16.5 %)	43 (12.4 %)	169 (100.0 %)	277 (100.0 %)
	yes	76 (83.5 %)	303 (87.6 %)	0 (0.0 %)	0 (0.0 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

		CASE		CONTROL	
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TRIO	SINGLETON
ACR/AER1 (ug/mg) (NON_ESRD ONLY):	n	7	7	115	200
	mean (std)	952.3 (618.0)	1839.2 (1532)	6.9 (4.9)	6.4 (4.3)
	minimum	318.5	416.7	1.0	1.2
	25th-percentile	483.1	636.1	3.8	3.6
	median	766.7	1306.4	5.2	5.2
	75th-percentile	1323.2	2766.7	8.5	8.1
	maximum	2138.3	4849.2	27.1	35.2
ACR/AER2 (ug/mg) (NON_ESRD ONLY):	n	15	43	169	277
	mean (std)	1226.6 (944.7)	1329.5 (1151)	6.5 (5.5)	6.3 (4.3)
	minimum	401.6	211.4	1.2	0.8
	25th-percentile	535.7	586.0	3.3	3.5
	median	685.4	877.5	4.8	5.1
	75th-percentile	1595.0	1697.0	7.3	7.7
	maximum	3378.9	5709.7	34.9	33.3
ACR/AER3 (ug/mg) (NON_ESRD ONLY):	n	3	15	18	19
	mean (std)	1052.9 (679.9)	799.4 (634.7)	5.8 (3.6)	8.1 (7.3)
	minimum	658.0	188.5	1.5	1.1
	25th-percentile	658.0	427.5	3.8	3.4
	median	662.6	627.9	4.8	4.8
	75th-percentile	1838.0	945.5	6.5	11.9
	maximum	1838.0	2896.6	16.9	30.6
CARDIOVASCULAR COMPLICATION:	no	7 (7.7 %)	22 (6.4 %)	146 (86.4 %)	238 (85.9 %)
	yes	84 (92.3 %)	324 (93.6 %)	23 (13.6 %)	39 (14.1 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		TRIO	SINGLETON	TRIO	SINGLETON
HYPERTENSIVE:	no	13 (14.3 %)	52 (15.0 %)	157 (92.9 %)	258 (93.1 %)
	yes	78 (85.7 %)	294 (85.0 %)	8 (4.7 %)	16 (5.8 %)
	unknown	0 (0.0 %)	0 (0.0 %)	1 (0.6 %)	0 (0.0 %)
	missing	0 (0.0 %)	0 (0.0 %)	3 (1.8 %)	3 (1.1 %)
NEUROPATHY DUE TO DIABETES:	no	29 (31.9 %)	86 (24.9 %)	157 (92.9 %)	245 (88.4 %)
	yes	58 (63.7 %)	257 (74.3 %)	10 (5.9 %)	30 (10.8 %)
	unknown	4 (4.4 %)	3 (0.9 %)	2 (1.2 %)	2 (0.7 %)
PERIPHERAL VASCULAR COMPLICATION:	no	47 (51.6 %)	173 (50.0 %)	162 (95.9 %)	268 (96.8 %)
	yes	44 (48.4 %)	173 (50.0 %)	7 (4.1 %)	9 (3.2 %)
GANGRENE:	no	81 (89.0 %)	302 (87.3 %)	169 (100.0 %)	275 (99.3 %)
	yes	10 (11.0 %)	42 (12.1 %)	0 (0.0 %)	2 (0.7 %)
	unknown	0 (0.0 %)	2 (0.6 %)	0 (0.0 %)	0 (0.0 %)
NON-TRAUMATIC AMPUTATION:	no	80 (87.9 %)	288 (83.2 %)	169 (100.0 %)	274 (98.9 %)
	yes	11 (12.1 %)	58 (16.8 %)	0 (0.0 %)	3 (1.1 %)
AUTO-IMMUNE DISEASE:	No	72 (79.1 %)	231 (66.8 %)	124 (73.4 %)	216 (78.0 %)
	Yes (with 1 disease)	15 (16.5 %)	91 (26.3 %)	41 (24.3 %)	51 (18.4 %)
	Yes (with >1 disease)	4 (4.4 %)	24 (6.9 %)	4 (2.4 %)	10 (3.6 %)
EVER SMOKED:	no	56 (61.5 %)	202 (58.4 %)	127 (75.1 %)	187 (67.5 %)
	yes	35 (38.5 %)	144 (41.6 %)	42 (24.9 %)	90 (32.5 %)
CURRENT SMOKER:	no	81 (89.0 %)	312 (90.2 %)	155 (91.7 %)	243 (87.7 %)
	yes	9 (9.9 %)	34 (9.8 %)	14 (8.3 %)	30 (10.8 %)
	missing	1 (1.1 %)	0 (0.0 %)	0 (0.0 %)	4 (1.4 %)
ABNORMAL SERUM CREATININE:	no	38 (41.8 %)	141 (40.8 %)	169 (100.0 %)	276 (99.6 %)
	yes	53 (58.2 %)	205 (59.2 %)	0 (0.0 %)	1 (0.4 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		TRIO	SINGLETON	TRIO	SINGLETON
SYSTOLIC BP (mm Hg):	n	89	337	157	267
	mean (std)	131.1 (19.5)	131.6 (20.0)	115.3 (12.4)	117.6 (12.5)
	minimum	79.5	51.0	86.0	83.0
	25th-percentile	118.0	118.0	107.0	109.5
	median	130.0	131.5	116.0	117.0
	75th-percentile	144.5	142.0	121.0	126.0
	maximum	178.0	188.0	158.0	159.0
DIASTOLIC BP (mm Hg):	n	89	337	157	267
	mean (std)	73.7 (11.9)	73.7 (11.3)	71.3 (8.4)	70.8 (8.0)
	minimum	40.0	41.0	50.0	48.5
	25th-percentile	67.5	67.0	65.0	65.5
	median	74.5	73.0	70.0	70.0
	75th-percentile	81.0	80.0	78.5	76.5
	maximum	99.0	130.0	94.0	98.0
BODY MASS INDEX (kg/m ²):	n	87	330	155	264
	mean (std)	25.8 (5.5)	25.2 (5.4)	26.3 (4.8)	26.4 (4.6)
	minimum	16.9	16.1	19.0	18.2
	25th-percentile	21.4	21.6	23.2	23.2
	median	25.3	24.1	24.9	25.6
	75th-percentile	28.4	27.7	28.3	28.7
	maximum	47.7	48.1	49.2	47.7

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

		CASE		CONTROL	
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TRIO	SINGLETON
NATURAL WAIST CIRCUM. (cm):	n	89	333	142	236
	mean (std)	88.6 (14.5)	89.4 (15.1)	84.0 (12.4)	86.9 (13.8)
	minimum	63.7	63.8	39.5	63.4
	25th-percentile	77.5	79.7	75.0	76.2
	median	87.0	86.8	83.6	85.3
	75th-percentile	98.8	97.0	90.7	95.5
	maximum	133.8	150.0	120.9	174.0
GFR(Cockcroft-Gault)(ml/min):	n	87	333	155	265
	mean (std)	63.9 (38.1)	60.0 (30.2)	114.1 (34.6)	111.4 (35.4)
	minimum	9.4	6.4	53.1	56.7
	25th-percentile	40.2	39.7	89.1	87.8
	median	56.1	56.8	112.1	103.3
	75th-percentile	76.0	79.2	129.7	126.8
	maximum	250.0	174.2	314.7	405.3
HBA1C (%):	n	90	337	168	276
	mean (std)	6.8 (1.9)	6.6 (1.7)	7.6 (1.2)	7.4 (1.1)
	minimum	4.1	3.0	5.1	4.8
	25th-percentile	5.3	5.3	6.8	6.6
	median	6.4	6.1	7.5	7.2
	75th-percentile	8.0	7.7	8.1	8.1
	maximum	12.9	13.4	12.3	11.0

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		TRIO	SINGLETON	TRIO	SINGLETON
TOTAL CHOLESTEROL (mg/dL):	n	88	339	151	240
	mean (std)	182.1 (40.8)	178.3 (43.4)	183.4 (33.9)	181.5 (31.2)
	minimum	103.0	63.0	101.0	111.0
	25th-percentile	148.0	148.0	158.0	161.5
	median	182.0	175.0	179.0	179.0
	75th-percentile	214.5	204.0	202.0	201.0
	maximum	271.0	376.0	289.0	311.0
HDL (mg/dL):	n	88	338	151	239
	mean (std)	50.5 (14.7)	53.1 (17.0)	56.2 (15.3)	57.4 (15.4)
	minimum	25.0	21.0	25.0	25.0
	25th-percentile	40.0	41.0	45.0	46.0
	median	48.5	50.0	54.0	56.0
	75th-percentile	60.5	62.0	66.0	68.0
	maximum	104.0	136.0	97.0	103.0
SERUM CREATININE (mg/dL):	n	88	339	166	270
	mean (std)	1.9 (1.4)	2.1 (1.9)	0.9 (0.1)	0.9 (0.2)
	minimum	0.8	0.5	0.6	0.5
	25th-percentile	1.2	1.1	0.8	0.8
	median	1.5	1.5	0.9	0.9
	75th-percentile	1.8	2.1	1.0	1.0
	maximum	8.8	15.5	1.3	1.4

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		TRIO	SINGLETON	TRIO	SINGLETON
SERUM CYSTATIN (mg/L):	n	82	328	141	237
	mean (std)	2.1 (1.0)	2.2 (1.7)	0.8 (0.1)	0.8 (0.1)
	minimum	0.7	0.5	0.5	0.5
	25th-percentile	1.5	1.3	0.7	0.7
	median	1.8	1.7	0.8	0.8
	75th-percentile	2.4	2.3	0.9	0.9
	maximum	6.3	12.0	1.1	1.8
TAKING LIPID LOWERING MEDICATION:	no	47 (51.6 %)	183 (52.9 %)	140 (82.8 %)	234 (84.5 %)
	yes	44 (48.4 %)	162 (46.8 %)	23 (13.6 %)	36 (13.0 %)
	missing	0 (0.0 %)	1 (0.3 %)	6 (3.6 %)	7 (2.5 %)
TAKING ACE INHIBITORS:	no	63 (69.2 %)	221 (63.9 %)	154 (91.1 %)	251 (90.6 %)
	yes	25 (27.5 %)	120 (34.7 %)	0 (0.0 %)	0 (0.0 %)
	missing	3 (3.3 %)	5 (1.4 %)	15 (8.9 %)	26 (9.4 %)
TAKING ANTI-HYPERTENSIVE DRUGS:	no	24 (26.4 %)	92 (26.6 %)	155 (91.7 %)	246 (88.8 %)
	yes	64 (70.3 %)	243 (70.2 %)	0 (0.0 %)	0 (0.0 %)
	missing	3 (3.3 %)	11 (3.2 %)	14 (8.3 %)	31 (11.2 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
GWU CLINICS - FINAL PHASE I GOKIND - DATA AS OF 18APR06

		CASE		CONTROL	
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TRIO	SINGLETON
TIME TO EVENT:	n	76	301	0	0
	mean (std)	24.6 (6.7)	25.1 (7.4)	. (.)	. (.)
	minimum	14.0	9.0	.	.
	25th-percentile	19.0	19.0	.	.
	median	24.5	24.0	.	.
	75th-percentile	29.0	30.0	.	.
	maximum	40.0	51.0	.	.
PANCREAS TRANSPLANT:	no	44 (48.4 %)	131 (37.9 %)	167 (98.8 %)	276 (99.6 %)
	yes	47 (51.6 %)	214 (61.8 %)	0 (0.0 %)	0 (0.0 %)
	missing	0 (0.0 %)	1 (0.3 %)	2 (1.2 %)	1 (0.4 %)
RENAL FUNCTION STATUS:	CONTROL	0 (0.0 %)	0 (0.0 %)	169 (100.0 %)	277 (100.0 %)
	PROTEINURIC	15 (16.5 %)	43 (12.4 %)	0 (0.0 %)	0 (0.0 %)
	DIALYSIS	5 (5.5 %)	13 (3.8 %)	0 (0.0 %)	0 (0.0 %)
	TRANSPLANT	71 (78.0 %)	290 (83.8 %)	0 (0.0 %)	0 (0.0 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs